BACKGROUND: Osteosarcoma survivors have received significant chemotherapy and have undergone substantial surgeries. Their very long-term outcomes (20 year) are reported here. METHODS: The authors assessed the long-term outcomes of 733 5-year survivors of childhood osteosarcoma diagnosed from 1970 to 1986 to provide a comprehensive evaluation of medical and psychosocial outcomes for survivors enrolled in the Childhood Cancer Survivor Study (CCSS). Outcomes evaluated included overall survival, second malignant neoplasms (SMNs), recurrent osteosarcoma, chronic health conditions, health status (general and mental health and functional limitations), and psychosocial factors. Outcomes of osteosarcoma survivors were compared with general-population statistics, other CCSS survivors, and CCSS siblings. RESULTS: Survivors had a mean follow-up of 21.6 years. The overall survival of children diagnosed with osteosarcoma who survived 5 years at 20 years from original diagnosis was 88.6% (95% confidence interval [CI], 86.6%-90.5%). The cumulative incidence of SMNs at 25 years was 5.4%, with a standardized incidence ratio of 4.79 (95% CI, 3.54-6.33; P<.01). Overall, 86.9% of osteosarcoma survivors experienced at least 1 chronic medical condition, and >50% experienced ≥2 conditions. Compared with survivors of other cancers, osteosarcoma survivors did not differ in their reported general health status (odds ratio [OR], 0.9; 95% CI, 0.7-1.2), but were more likely to report an adverse health status in at least 1 domain (OR, 1.9; 95% CI, 1.6-2.2), with activity limitations (29.1%) being the most common. CONCLUSIONS: Childhood osteosarcoma survivors in this cohort did relatively well, considering their extensive treatment, but are at risk of experiencing chronic medical conditions and adverse health status. Survivors warrant life-long follow-up.
BACKGROUND:Osteosarcoma survivors have received significant chemotherapy and have undergone substantial surgeries. Their very long-term outcomes (20 year) are reported here. METHODS: The authors assessed the long-term outcomes of 733 5-year survivors of childhood osteosarcoma diagnosed from 1970 to 1986 to provide a comprehensive evaluation of medical and psychosocial outcomes for survivors enrolled in the Childhood Cancer Survivor Study (CCSS). Outcomes evaluated included overall survival, second malignant neoplasms (SMNs), recurrent osteosarcoma, chronic health conditions, health status (general and mental health and functional limitations), and psychosocial factors. Outcomes of osteosarcoma survivors were compared with general-population statistics, other CCSS survivors, and CCSS siblings. RESULTS: Survivors had a mean follow-up of 21.6 years. The overall survival of children diagnosed with osteosarcoma who survived 5 years at 20 years from original diagnosis was 88.6% (95% confidence interval [CI], 86.6%-90.5%). The cumulative incidence of SMNs at 25 years was 5.4%, with a standardized incidence ratio of 4.79 (95% CI, 3.54-6.33; P<.01). Overall, 86.9% of osteosarcoma survivors experienced at least 1 chronic medical condition, and >50% experienced ≥2 conditions. Compared with survivors of other cancers, osteosarcoma survivors did not differ in their reported general health status (odds ratio [OR], 0.9; 95% CI, 0.7-1.2), but were more likely to report an adverse health status in at least 1 domain (OR, 1.9; 95% CI, 1.6-2.2), with activity limitations (29.1%) being the most common. CONCLUSIONS:Childhood osteosarcoma survivors in this cohort did relatively well, considering their extensive treatment, but are at risk of experiencing chronic medical conditions and adverse health status. Survivors warrant life-long follow-up.
Authors: J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis Journal: Psychosomatics Date: 2001 May-Jun Impact factor: 2.386
Authors: Elvira C van Dalen; Helena J H van der Pal; Wouter E M Kok; Huib N Caron; Leontien C M Kremer Journal: Eur J Cancer Date: 2006-09-20 Impact factor: 9.162
Authors: LeLe Aung; Richard G Gorlick; Weiji Shi; Howard Thaler; Nicholas A Shorter; John H Healey; Andrew G Huvos; Paul A Meyers Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 11.816
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Pinki K Prasad; Lisa B Signorello; Debra L Friedman; John D Boice; Eero Pukkala Journal: Pediatr Blood Cancer Date: 2011-09-09 Impact factor: 3.167
Authors: Jacqueline Casillas; Kevin C Oeffinger; Melissa M Hudson; Mark L Greenberg; Mark W Yeazel; Kirsten K Ness; Tara O Henderson; Leslie L Robison; Gregory T Armstrong; Qi Liu; Wendy Leisenring; Yutaka Yasui; Paul C Nathan Journal: Health Serv Res Date: 2015-01-20 Impact factor: 3.402
Authors: Michael W Bishop; Kirsten K Ness; Chenghong Li; Wei Liu; Deo Kumar Srivastava; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Alberto S Pappo; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-04 Impact factor: 4.254
Authors: Anne C Kirchhoff; Mark N Fluchel; Jennifer Wright; Jian Ying; Carol Sweeney; Julia Bodson; Antoinette M Stroup; Ken R Smith; Alison Fraser; Anita Y Kinney Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-12 Impact factor: 4.254
Authors: Neyssa Marina; Melissa M Hudson; Kendra E Jones; Daniel A Mulrooney; Raffi Avedian; Sarah S Donaldson; Rita Popat; Dee W West; Paul Fisher; Wendy Leisenring; Marilyn Stovall; Leslie L Robison; Kirsten K Ness Journal: Arch Phys Med Rehabil Date: 2013-02-01 Impact factor: 3.966
Authors: Tara M Brinkman; Nicole J Ullrich; Nan Zhang; Daniel M Green; Lonnie K Zeltzer; Karen M Lommel; Pim Brouwers; Deo Kumar Srivastava; Neelam Jain; Leslie L Robison; Kevin R Krull Journal: J Cancer Surviv Date: 2012-12-08 Impact factor: 4.442
Authors: Israel Fernandez-Pineda; M M Hudson; A S Pappo; M W Bishop; J L Klosky; T M Brinkman; D K Srivastava; M D Neel; B N Rao; A M Davidoff; K R Krull; D A Mulrooney; L L Robison; K K Ness Journal: J Cancer Surviv Date: 2016-06-04 Impact factor: 4.442